ATLANTIC THERAPEUTICS UK LIMITED

Company Registration Number:
10492389 (England and Wales)

Unaudited abridged accounts for the year ended 28 February 2023

Period of accounts

Start date: 01 March 2022

End date: 28 February 2023

ATLANTIC THERAPEUTICS UK LIMITED

Contents of the Financial Statements

for the Period Ended 28 February 2023

Balance sheet
Notes

ATLANTIC THERAPEUTICS UK LIMITED

Balance sheet

As at 28 February 2023


Notes

2023

2022


£

£
Current assets
Debtors:   729,269 1,588,349
Cash at bank and in hand: 21,758 386,200
Total current assets: 751,027 1,974,549
Creditors: amounts falling due within one year:   (599,475) (1,834,349)
Net current assets (liabilities): 151,552 140,200
Total assets less current liabilities: 151,552 140,200
Total net assets (liabilities): 151,552 140,200
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 151,551 140,199
Shareholders funds: 151,552 140,200

The notes form part of these financial statements

ATLANTIC THERAPEUTICS UK LIMITED

Balance sheet statements

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 29 September 2023
and signed on behalf of the board by:

Name: Daniel Forde, Paul Murray
Status: Director

The notes form part of these financial statements

ATLANTIC THERAPEUTICS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Revenue is recognised to the extent that it is probable that the economic benefits will flow to theCompany and the revenue can be reliably measured. Revenue is measured as the fair value of theconsideration received or receivable, excluding discounts, rebates, value added tax and other salestaxes. The following criteria must also be met before revenue is recognised:Rendering of servicesRevenue from a contract to provide services is recognised in the period in which the services areprovided in accordance with the stage of completion of the contract when all of the followingconditions are satisfied:- the amount of revenue can be measured reliably;- it is probable that the Company will receive the consideration due under the contract;- the stage of completion of the contract at the end of the reporting period can be measuredreliably; and- the costs incurred and the costs to complete the contract can be measured reliably.

ATLANTIC THERAPEUTICS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

2. Employees

2023 2022
Average number of employees during the period 2 4

ATLANTIC THERAPEUTICS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

3. Related party transactions

Related party transactionsThe company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure oftransactions with group undertakings.

ATLANTIC THERAPEUTICS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

4. Post balance sheet events

Atlantic Therapeutics UK Limited parent company Atlantic Therapeutics Limited recently sold all its assets toa US company on the 1st Sept 2023. The parent company will no longer have a requirement for the servicesof Atlantic Therapeutics UK Limited and the future of the company is being actively reviewed